Rikke Ibsen
Rikke Ibsen has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Jakob Kjellberg
VIVE-The Danish Center for Social Science Research, Copenhagen, Denmark
12 shared publications - Poul Jennum
Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark
11 shared publications - Anders Løkke
Department of Medicine, Little Belt Hospital, 7100 Vejle, Denmark
5 shared publications - Ole Hilberg
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
4 shared publications - Lone Baandrup
Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Charlotte Suppli Ulrik
Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark
2 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by Elsevier in Sleep Medicine
- Vol. 141, 108822
Clinical phenotypes and predictors of adherence to continuous positive airway pressure therapy in obstructive sleep apnoea: A multicentre cohort study
- 3 February 2026
- Published by Elsevier in Sleep Medicine
- Vol. 141, 108822
Open AccessClinical phenotypes and predictors of adherence to continuous positive airway pressure therapy in obstructive sleep apnoea: A multicentre cohort study
- Open Access
- 2 February 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 67
Individual and Societal Economic Burden of Chronic Rhinosinusitis with or Without Nasal Polyps
Background/Objectives: Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without NP (CRSsNP) are common upper airway diseases with major impact on healthcare utilization. Little is known about the overall national financial burden of CRS. We aimed to assess the excess financial burden of CRS from a countrywide perspective. Methods: Annual expenditure from healthcare, welfare transfers and foregone income was retrieved from national databases, annualized and compared to matched healthy comparators. Results: Of the 303,475 patients included with CRS (mean age 51, 55% female), 18,142 were subclassified as CRSsNP (24%) or CRSwNP (76%). For CRS patients, annual excess healthcare costs were €1315 (1296–1333) compared to comparators. Patients with CRS earned €1356 (1230–1479) less annually compared to comparators. Patients with CRS of working age (18–64 years) had excess welfare transfers (€816 (782–850) compared to comparators, driven by sick leave and disability. Increases in healthcare costs were seen for patients with CRSwNP (€5406 (4860–6012) annually) compared to CRSsNP (€4945 (4293–5696)) driven by increases in CRS-related costs. Total societal burden for the entire cohort was €686,052,898, of which systemic corticosteroid exposure-related conditions represented €20,332,825. Excess welfare transfers represented €174,394,048 annually. Conclusions: Chronic rhinosinusitis is associated with a significant financial burden, both in terms of societal healthcare and welfare expenditure and patients’ personal finances due to lost income.
- 2 February 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 67
Open AccessIndividual and Societal Economic Burden of Chronic Rhinosinusitis with or Without Nasal Polyps
Background/Objectives: Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without NP (CRSsNP) are common upper airway diseases with major impact on healthcare utilization. Little is known about the overall national financial burden of CRS. We aimed to assess the excess financial burden of CRS from a countrywide perspective. Methods: Annual expenditure from healthcare, welfare transfers and foregone income was retrieved from national databases, annualized and compared to matched healthy comparators. Results: Of the 303,475 patients included with CRS (mean age 51, 55% female), 18,142 were subclassified as CRSsNP (24%) or CRSwNP (76%). For CRS patients, annual excess healthcare costs were €1315 (1296–1333) compared to comparators. Patients with CRS earned €1356 (1230–1479) less annually compared to comparators. Patients with CRS of working age (18–64 years) had excess welfare transfers (€816 (782–850) compared to comparators, driven by sick leave and disability. Increases in healthcare costs were seen for patients with CRSwNP (€5406 (4860–6012) annually) compared to CRSsNP (€4945 (4293–5696)) driven by increases in CRS-related costs. Total societal burden for the entire cohort was €686,052,898, of which systemic corticosteroid exposure-related conditions represented €20,332,825. Excess welfare transfers represented €174,394,048 annually. Conclusions: Chronic rhinosinusitis is associated with a significant financial burden, both in terms of societal healthcare and welfare expenditure and patients’ personal finances due to lost income.
- Open Access
- 2 December 2025
- Published by Elsevier in Sleep Medicine
- Vol. 139, 108690
Clinical and socioeconomic burden among people with narcolepsy or idiopathic hypersomnia: A retrospective cohort analysis of the Danish National Patient Registry
- 2 December 2025
- Published by Elsevier in Sleep Medicine
- Vol. 139, 108690
Open AccessClinical and socioeconomic burden among people with narcolepsy or idiopathic hypersomnia: A retrospective cohort analysis of the Danish National Patient Registry
- Open Access
- 5 March 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1246-1256
The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma
IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.
- 5 March 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1246-1256
Open AccessThe impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma
IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.
- 8 January 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 182, 212-220
Long-term effects of attention deficit hyperactivity disorder (ADHD) on social functioning and health care outcomes
- 8 January 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 182, 212-220
Long-term effects of attention deficit hyperactivity disorder (ADHD) on social functioning and health care outcomes
- Open Access
- 28 March 2024
- Published by Elsevier in Sleep Medicine
- Vol. 118, 93-100
Real-world impact of continuous positive airway pressure on sleepiness in patients with obstructive sleep apnea in a national registry
- 28 March 2024
- Published by Elsevier in Sleep Medicine
- Vol. 118, 93-100
Open AccessReal-world impact of continuous positive airway pressure on sleepiness in patients with obstructive sleep apnea in a national registry
- Open Access
Nationwide Increasing Incidence of Nontuberculous Mycobacterial Diseases Among Adults in Denmark
- Open Access
- 5 February 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 372
National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018
Recommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use of inhaled corticosteroids (ICS). We aimed to identify the nationwide development over time in the use of ICS treatment in COPD. We conducted a register-based repeated cross-sectional study using Danish nationwide registers. On a yearly basis from 1998 to 2018, we included all patients in Denmark ≥ 40 years of age with an ICD-10 diagnosis of COPD (J44). Accumulated ICS use was calculated for each year based on redeemed prescriptions. Patients were divided into the following groups: No ICS, low-dose ICS, medium-dose ICS, or high-dose ICS. From 1998 to 2018, the yearly proportion of patients without ICS treatment increased (from 50.6% to 57.6%), the proportion of patients on low-dose ICS treatment increased (from 11.3% to 14.9%), and the proportion of patients on high-dose ICS treatment decreased (from 17.0% to 9.4%). We demonstrated a national reduction in the use of ICS treatment in COPD from 1998 to 2018, with an increase in the proportion of patients without ICS and on low-dose ICS treatment and a decrease in the proportion of patients on high-dose ICS treatment.
- 5 February 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 372
Open AccessNational Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018
Recommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use of inhaled corticosteroids (ICS). We aimed to identify the nationwide development over time in the use of ICS treatment in COPD. We conducted a register-based repeated cross-sectional study using Danish nationwide registers. On a yearly basis from 1998 to 2018, we included all patients in Denmark ≥ 40 years of age with an ICD-10 diagnosis of COPD (J44). Accumulated ICS use was calculated for each year based on redeemed prescriptions. Patients were divided into the following groups: No ICS, low-dose ICS, medium-dose ICS, or high-dose ICS. From 1998 to 2018, the yearly proportion of patients without ICS treatment increased (from 50.6% to 57.6%), the proportion of patients on low-dose ICS treatment increased (from 11.3% to 14.9%), and the proportion of patients on high-dose ICS treatment decreased (from 17.0% to 9.4%). We demonstrated a national reduction in the use of ICS treatment in COPD from 1998 to 2018, with an increase in the proportion of patients without ICS and on low-dose ICS treatment and a decrease in the proportion of patients on high-dose ICS treatment.
- Open Access
- 23 June 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 107, 162-171
Estimates of epilepsy prevalence, psychiatric co-morbidity and cost
- 23 June 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 107, 162-171
Open AccessEstimates of epilepsy prevalence, psychiatric co-morbidity and cost
- 20 May 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (8) , 1880-1885
Direct and indirect costs of heart failure in relation to diabetes status - A nationwide study
- 20 May 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (8) , 1880-1885
Direct and indirect costs of heart failure in relation to diabetes status - A nationwide study